1,721,008 research outputs found

    Gonadotropin-releasing hormone antagonists increase follicular fluid insulin-like growth factor-I and vascular endothelial growth factor during ovarian stimulation cycles.

    No full text
    The aim of the present study was to investigate the effect of gonadotropin-releasing hormone (GnRH) antagonists (GnRH-ant) on follicular fluid (FF) insulin-like growth factor-I (IGF-I) and FF vascular endothelial growth factor (VEGF) levels. Sixty women undergoing assisted reproduction were randomized and assigned to two different GnRH analog regimens: GnRH agonist (GnRH-a) and GnRH-ant. FF VEGF and FF IGF-I concentrations were significantly increased in the patients treated with GnRH-ant (ρ<0.001). In the same patients we observed a statistically significant reduction in serum luteinizing hormone (LH) and estradiol (E2 ) levels (ρ<0.001 and ρ<0.05, respectively), FF E2 and FF androstenedione levels (ρ<0.05 and ρ<0.001, respectively), as well as a reduction in the number of pregnancies although this was not statistically significant. In the GnRH-ant group, FF VEGF levels were positively correlated with FF IGF-I levels, and both were negatively correlated with serum LH levels. The increase in FF IGF-I and FF VEGF levels in women treated with GnRH-ant could be explained by a deleterious follicular environment in response to profound suppression of LH and E2 levels

    Follicular fluid vascular endothelial growth factor concentrations are increased during GnRH antagonist/FSH ovarian stimulation cycles.

    No full text
    Background: The aim of this study was to investigate the effect of GnRH antagonists (GnRH-ant) on follicular fluid vascular endothelial growth factor (FF VEGF). Methods: Sixty women undergoing assisted reproduction were randomised (computer-generated randomisation list) and assigned to two different GnRH analogue regimens: GnRH agonist (GnRH-a) (Group A; n = 30) and GnRH-ant (Group B; n = 30). Results: Mean (S.D.) FF VEGF concentrations were 1598 612 pg/mL and 2906 1558 pg/mL for Groups A and B, respectively ( p < 0.001). In the women treated with GnRH-ant, we found a statistically significant reduction in serum LH levels (1.72 0.74 IU/L in Group A versus 0.93 0.43 IU/L in Group B, p < 0.001), in serum oestradiol (E2) levels (1562.1 410.7 pg/mL in Group A versus 1214.67 779.9 pg/mL in Group B, p < 0.05), in FF E2 levels (1146 593 ng/mL in Group A versus 621 435 ng/mL in Group B, p < 0.05), and in FF androstenedione levels (136 55 ng/mL in Group A versus 78 31 ng/mL in Group B, p < 0.001), as well as a reduction in the number of pregnancies, though not statistically significant (23.3% in Group A versus 16.6% in Group B). Conclusion: The increase in FF VEGF levels in women treated with GnRH-ant might be explained by a suppression of LH and E2 levels
    corecore